通过毒理学测试对维生素K2 (menaquinone-7) 的安全评估
Sung-Bong Hwang1, Min-Ju Choi1, Hyeon-Jeong Lee1
1Department of Quality, GF Fermentech, Inc., Sejong, 30077, South Korea.
Scientific reports
|March 5, 2024
概括
发酵衍生的维生素K2 (MK-7) 来自 Bacillus subtilis var. 纳托对人类摄入是安全的. 毒性和基因毒性测试证实没有不良影响,确定了高无观察不良影响水平 (NOAEL).
科学领域:
- 食品科学与技术 食品科学与技术
- 毒理学 毒理学 毒理学
- 微生物学 微生物学
背景情况:
- 维生素K2,特别是menaquinone-7 (MK-7),对于骨和心血管健康至关重要.
- 使用Bacillus subtilis var.进行发酵. natto是生产MK-7的一种常见方法.
研究的目的:
- 评估通过发酵生产的人类消费的MK-7的安全性.
- 通过各种安全评估来评估潜在的毒理效应.
主要方法:
- 急性口服毒性测试 (5000毫克/公斤).
- 在老鼠中进行90天的重复剂量口服毒性试验 (500,1500,4500 mg/kg/d).
- 基因毒性测试:反向突变,染色体异常和微核测试.
主要成果:
- 在急性口服毒性测试中没有观察到死亡率或毒性影响.
- 在90天的重复剂量研究中,无观察不良影响水平 (NOAEL) 确定为4500 mg/kg/d.
- 所有的基因毒性测试 (反向突变,染色体异常,微核) 均呈阴性,表明没有变种或克拉斯托基因潜力.
结论:
- 由Bacillus subtilis var.产生的MK-7是一种 纳托发酵是安全的人类摄入.
- 这项研究确定了这种发酵衍生维生素K2的高安全性.
- 在经过测试的实验条件下,没有发现有毒性问题.
相关概念视频
Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Bioactivation and Tissue Toxicity
Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
Toxicokinetics: Overview
Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...
Toxicity Testing in Animals
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...


